Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem
Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · 26.06.2026 · 22 (3) · 319-326
DOI: 10.48036/apims.v22i3.1690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, online erschienen am 26.06.2026. Verfasst von Zahid Hussain und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To compare the real-world clinical outcomes, time to clinical cure of patients with Extended-spectrum b-lactamase-producing Enterobacterales (ESBL-E) pyelonephritis who received cefoperazone-sulbactam versus meropenem based on retrospective medical record review.
Objective
To compare the real-world clinical outcomes, time to clinical cure of patients with Extended-spectrum b-lactamase-producing Enterobacterales (ESBL-E) pyelonephritis who received cefoperazone-sulbactam versus meropenem based on retrospective medical record review. Methodology: A retrospective cohort study was done at the Department of Infectious Diseases, Indus Hospital and Health Network (IHHN), Karachi, on adult patients with culture-proven ESBL-producing Enterobacterales pyelonephritis treated between January 2008 and December 2024. Data were collected using a structured questionnaire that captured demographic characteristics, clinical findings, and outcomes, including survival status, physician-assessed clinical improvement, infection-related complications, hospitalization, mortality, and clinical status at follow-up.
Results
Overall mean age of 48.9+15.81 years and females were in majority 119 (73.5%) compared to males 43 (26.5%). Meropenem-treated patients had higher baseline severity, with higher SOFA scores (3.7 vs 2.3, p = 0.002), Charlson Comorbidity Index (3.6 vs 2.0, p = 0.001), compared to cefoperazone-sulbactam-treated cases. However, the primary and secondary outcomes were statistically comparable across the groups: in terms of composite clinical failure which occurred in 6.3% (meropenem) versus 6.1% (cefoperazone-sulbactam) p = 1.000, relapse in 12.6% versus 4.5% (p = 0.101), and 30-day mortality in 5.3% versus 0.0% (p = 0.077), with no significant differences in rehospitalization rate and microbiological non-response.
Conclusion
Cefoperazone–sulbactam appeared to be a clinically feasible and effective carbapenem-sparing alternative to meropenem for the treatment of ESBL-producing Enterobacterales pyelonephritis. Although it was used more frequently in less critically ill patients, it was associated with clinical and microbiological outcomes comparable to those observed with meropenem.
Results
Overall mean age of 48.9+15.81 years and females were in majority 119 (73.5%) compared to males 43 (26.5%). Meropenem-treated patients had higher baseline severity, with higher SOFA scores (3.7 vs 2.3, p = 0.002), Charlson Comorbidity Index (3.6 vs 2.0, p = 0.001), compared to cefoperazone-sulbactam-treated cases. However, the primary and secondary outcomes were statistically comparable across the groups: in terms of composite clinical failure which occurred in 6.1% (meropenem) versus 6.3% (cefoperazone-sulbactam) p = 1.000, relapse in 12.6% versus 4.5% (p = 0.101), and 30-day mortality in 5.3% versus 0.0% (p = 0.077), with no significant differences in rehospitalization rate and microbiological non-response.
Conclusion
Cefoperazone–sulbactam appeared to be a clinically feasible and effective carbapenem-sparing alternative to meropenem for the treatment of ESBL-producing Enterobacterales pyelonephritis. Although it was used more frequently in less critically ill patients, it was associated with clinical and microbiological outcomes comparable to those observed with meropenem.
Zitieren
APA
Hussain, Z., Kazi, A. S., Hussain, I., Saleem, H., Nadeem, H., & Sarfaraz, S. (2026). Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, 22(3), 319-326. https://doi.org/10.48036/apims.v22i3.1690
Vancouver
Hussain Z, Kazi AS, Hussain I, Saleem H, Nadeem H, Sarfaraz S. Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University. 2026;22(3):319-326. doi:10.48036/apims.v22i3.1690
BibTeX
@article{Hussain2026,
author = {Hussain, Zahid and Kazi, Aamir Sikander and Hussain, Imtiaz and Saleem, Hira and Nadeem, Hira and Sarfaraz, Samreen},
title = {Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem},
journal = {Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University},
year = {2026},
volume = {22},
number = {3},
pages = {319--326},
doi = {10.48036/apims.v22i3.1690}
}
EUVIMED